Sophia Genetics(US:SOPH)2026-03-03 14:02Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $21.7 million, a 22% increase from $17.7 million in Q4 2024 [30] - Full-year 2025 revenue reached $77.3 million, representing a 19% year-over-year growth [34] - Gross profit for Q4 2025 was $14.7 million, up 21% from $12.1 million in the prior year [30] - Adjusted gross margin for the full-year 2025 increased by 140 basis points to 74.2% [36] Business Line Data and Key Metrics Changes - Clinical revenue, excluding biopharma, grew 31% year-over-year in Q4 2025 [16] - The company signed a record 124 new customers in 2025, with an average contract value up 120% year-over-year [19] - Platform analysis volume was over 105,000 in Q4 2025, a 16% increase from 91,000 in Q4 2024 [30] Market Data and Key Metrics Changes - EMEA region grew 22% in Q4 2025, with clinical revenue up 35% year-over-year [17] - North America saw analysis volumes grow 45% year-over-year in Q4 2025 [17] - Asia Pacific revenue grew 44% in Q4 2025, driven by India and Australia [18] Company Strategy and Development Direction - The company is focused on expanding its AI capabilities and has launched initiatives like Digital Twins to enhance patient care [12] - SOPHiA GENETICS aims to continue its growth trajectory by leveraging its extensive customer network and enhancing its platform [14] - The transition in leadership to Ross Muken as CEO is expected to drive the next phase of growth [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory, highlighting strong demand and a robust pipeline [44] - The company expects full-year 2026 revenue to be between $92 million and $94 million, representing 20%-22% growth [40] - Adjusted EBITDA loss is projected to decrease to between $29 million and $32 million in 2026 [41] Other Important Information - The company processed nearly 1 petabyte of genomic data in 2025, nearly double the amount processed two years ago [8] - Annualized revenue churn was at a record low of less than 1% for 2025 [35] - The company raised $15.5 million in net proceeds through an at-the-market facility [33] Q&A Session Questions and Answers Question: What contributions are expected from key growth drivers such as MSK-ACCESS and IMPACT? - Management highlighted that the ramping of MSK-ACCESS continues to be a significant driver, with sizable customers starting to come online [48][49] Question: Can you speak to the net dollar retention increase to 115% and what drove the cross-selling strength? - Management noted that the low churn rate and re-acceleration of volumes in oncology and rare disease contributed to the strong net dollar retention [52][54] Question: What is the potential annual contribution from new pharma contracts? - Management indicated that while the pharma business takes time to ramp, they expect a net positive contribution in 2026 [60][61] Question: How do you assess the potential for the two large health systems added? - Management expressed optimism about the potential for significant growth from these accounts, with opportunities for expansion in the future [63][65]